Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).
JAMA, 285 (2001), pp. 2486-2497
[2.]
G. De Backer, E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cifkova, J. Dallongeville, et al.
European guidelines on cardiovascular disease prevention in clinical practice. third joint task force of european and other societies on cardiovascular disease prevention in clinical practice.
Atherosclerosis, 173 (2004), pp. 381-391
[3.]
C. Brotons, J. Casanovas, A. Iruela, R. Vinyeta, A. Bartés, M. Martínez, et al.
Utilización del cálculo del riesgo cardiovascular para el control y tratamiento de las dislipemias en atención primaria.
Clin invest arterioscler, 16 (2004), pp. 240-246
[4.]
J. Marrugat, P. Solana, R. D’Agostino, L. Sullivan, J. Ordovas, F. Cordón, et al.
Estimación del riesgo coronario en españa mediante la ecuación de framingham calibrada.
Rev esp cardiol, 56 (2003), pp. 253-261
[5.]
C. Brotons, M.A. Royo-Bordonada, L. Álvarez-Sala, P. Armario, R. Artigao, P. Conthe, et al.
Comité español interdisciplinario para la prevencion cardiovascular. adaptación española de la guía europea de prevención cardiovascular.
Rev esp salud publica, 78 (2004), pp. 435-438
[6.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. west of scotland coronary prevention study group.
N engl j med, 333 (1995), pp. 1301-1307
[7.]
J.R. Downs, M. learfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, et al.
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. air force/texas.coronary atherosclerosis prevention study.
JAMA, 279 (1998), pp. 1615-1622
[8.]
P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial –lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet, 361 (2003), pp. 1149-1158
[9.]
H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebocontrolled trial.
Lancet, 364 (2004), pp. 685-696
[10.]
G. Abhimanyu.
Statins for all patients with type 2 diabetes: not so soon.
Lancet, 364 (2004), pp. 641
[11.]
C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, et al.
The pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N engl j med, 350 (2004), pp. 1495-1504
[12.]
S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Jr. Brewer, L.T. Clark, D.B. Hunninghake, et al.
Coordinating committee of the national cholesterol education program; national heart, lung, and blood institute; american college of cardiology foundation; american heart association. implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines.
Arterioscler thromb vasc biol, 24 (2004), pp. 149-161
Copyright © 2004. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.